<DOC>
	<DOC>NCT01008436</DOC>
	<brief_summary>The study enrolles all consecutive patients undergoing cardiac surgery at the European Hospital, Rome. The population undergoes randomization to receive usual surgical hemostasis or added topical application of Omni-stat Celox. The two populations are followed up prospectively as regarding blood loss and need for blood transfusions, as well as adverse events at 30 days after surgery.</brief_summary>
	<brief_title>Blood Sparing Strategies: Omni-stat Routinary Use in Cardiac Surgery. A Prospective Randomized Study.</brief_title>
	<detailed_description />
	<mesh_term>Chitosan</mesh_term>
	<criteria>All patients undergoing heart surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Ability of topical drug to reduce acute and overall bleeding as well as blood transfusions</keyword>
</DOC>